modelling and simulation group, school of pharmacy for clinical pharmacist clinical pharmacology

29
Modelling and Simulation Group, School of Pharmacy For Clinical Pharmacist Clinical Pharmacology

Upload: teresa-wood

Post on 28-Dec-2015

224 views

Category:

Documents


2 download

TRANSCRIPT

Modelling and Simulation Group, School of Pharmacy

For Clinical Pharmacist

Clinical Pharmacology

Modelling and Simulation Group, School of Pharmacy

Abbreviation Spoiler Alert

• PK = Pharmacokinetics

• PD = Pharmacodynamics

• PG = Pharmacogenomics

• PO = Per Os

• PM = Post Meridiem

• PC = Personal Computer

BARRY = Clinical Pharmacology

Modelling and Simulation Group, School of Pharmacy

Educational Objectives

• By the end of this session you should be able to: – Feel less daunted by Barry – Understand how Barry complements evidence

based practice– Provide rationale recommendations for

aminoglycoside monitoring

Modelling and Simulation Group, School of Pharmacy

OVERVIEW

• Who is Barry?

• What can Barry do for me?

• What does Barry want from me?

• How do I get the most out of Barry

Modelling and Simulation Group, School of Pharmacy

Barry as an equation

BARRY =

DISEASE PROGRESS

+

DRUG ACTION

Modelling and Simulation Group, School of Pharmacy

Disease progression

Modelling and Simulation Group, School of Pharmacy

Drug Action

Modelling and Simulation Group, School of Pharmacy

Concentration Time Profiles following administration of IV paracetamol to neonates

2011, Anderson and Holford et al.

Modelling and Simulation Group, School of Pharmacy

OVERVIEW

• Who is Barry?

• What can Barry do for me?

• What does Barry want from me?

• How do I get the most out of Barry

Modelling and Simulation Group, School of Pharmacy

What can Barry Do for me

• Understanding Barry can make you a better clinical pharmacist through improving evidence based practice.

www.homeopathyworldcommunity.com/

Modelling and Simulation Group, School of Pharmacy

Clinical Pharmacy

Sufficient Outcome for a patient

=

(Drug Action/Blah)Concordance

Warning Blah may contain traces of actual evidence, dosage

regimen,legislation, pharmacoeconomics, local policy, personal

preference, sales representative influence, health beliefs of the patient,

nocebo/placebo effect, stock availability, etc)

Modelling and Simulation Group, School of Pharmacy

OVERVIEW

• Who is Barry?

• What can Barry do for me?

• What does Barry want from me?

• How do I get the most out of Barry

Modelling and Simulation Group, School of Pharmacy

Starting a relationship with Barry

• PK– First Order Kinetics– AUC– Clearance– Half Life

Modelling and Simulation Group, School of Pharmacy

First Order Kinetics

Modelling and Simulation Group, School of Pharmacy

Modelling and Simulation Group, School of Pharmacy

MDR = CPave,ss X Cl

Modelling and Simulation Group, School of Pharmacy

• PD

Chapter 8. Principles of Pharmacokinetics and PharmacodynamicsC. Lindsay DeVane, Pharm.D.

DOI: 10.1176/appi.books.9781585623860.408715

Modelling and Simulation Group, School of Pharmacy

OVERVIEW

• Who is Barry?

• What can Barry do for me?

• What does Barry want from me?

• How do I get the most out of Barry

Modelling and Simulation Group, School of Pharmacy

TDM VS TCI

Modelling and Simulation Group, School of Pharmacy

• Once daily dosing – from AMH

“Methods for monitoring drug concentration include graphical, trough plasma concentration and target AUC (area under the plasma concentration – time curve) methods. Not all are valid for use in renal impairment.

Although no method is proven to be clinically superior, the current preferred, but most complex, method is based on target AUC (can be used in renal impairment). It requires 2 samples: collect the first about 30 minutes after completing the infusion/injection and the second 6–14 hours later. The estimated 24-hour AUC is generally calculated using a computer program, eg the one available from TCIWorks at www.tciworks.info.”

Modelling and Simulation Group, School of Pharmacy

What Does QHealth have to Say

Modelling and Simulation Group, School of Pharmacy

AMINOGLYCOSIDE MONITORING

• Trough Concentrations

• 6-14 Hour Nomogram

• Target AUC– Bayesian Forecasting

Modelling and Simulation Group, School of Pharmacy

Modelling and Simulation Group, School of Pharmacy

Bayesian Forecasting

Disclamer regarding TCI works

Modelling and Simulation Group, School of Pharmacy

Modelling and Simulation Group, School of Pharmacy

• You (as the junior doctor) are told by your consultant to write up gentamicin for Beryl. You haven’t met Beryl but you have seen that her sputum sample is positive for pseudomonas.

• What would you do next.

Modelling and Simulation Group, School of Pharmacy

Questions for Cases

• Later that day you are ask to provide advice regarding monitoring for gentamicin in a woman about to have a caesarean birth.

• What would you ask and recommend?

Modelling and Simulation Group, School of Pharmacy

• 5 days later Beryl from case 1 has a blood sample taken at 8:50pm, it is sent to the lab for assay. The next morning at 10:30 on the ward round the doctor reviews the result (1mg/L) and rings the pharmacist for advice.

• What do you do?

Modelling and Simulation Group, School of Pharmacy

• A further 3 days pass and Beryl is looking better. The doctors want your fantastic and friendly pharmacist advice regarding monitoring.

• What do you say?